ITOSiTeos Therapeutics, Inc.

Nasdaq iteostherapeutics.com


$ 12.13 $ 0.03 (0.25 %)    

Tuesday, 17-Sep-2024 15:59:41 EDT
QQQ $ 473.83 $ -2.14 (-0.45 %)
DIA $ 417.12 $ -0.26 (-0.06 %)
SPY $ 563.14 $ 0.30 (0.05 %)
TLT $ 100.82 $ -0.51 (-0.5 %)
GLD $ 237.35 $ -1.31 (-0.55 %)
$ 12.1
$ 12.11
$ 12.11 x 200
-- x --
$ 11.80 - $ 12.28
$ 8.20 - $ 18.75
5,791,008
na
441.91M
$ 0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-06-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-15-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-23-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-24-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 09-01-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrol...

 hc-wainwright--co-reiterates-buy-on-iteos-therapeutics-maintains-46-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:ITOS) with a Buy and maintains ...

Core News & Articles

Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with co...

 wells-fargo-initiates-coverage-on-iteos-therapeutics-with-overweight-rating-announces-price-target-of-31

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on ITeos Therapeutics (NASDAQ:ITOS) with a Overweight rating and a...

 jp-morgan-maintains-overweight-on-iteos-therapeutics-lowers-price-target-to-24

JP Morgan analyst Brian Cheng maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from ...

Core News & Articles

This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug. iTeos and GSK en...

Core News & Articles

iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery a...

 hc-wainwright--co-maintains-buy-on-iteos-therapeutics-raises-price-target-to-46

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ITeos Therapeutics (NASDAQ:ITOS) with a Buy and raises the ...

Core News & Articles
Market-Moving News for May 10th
05/10/2024 12:41:27

ITOS: 39% | iTeos Therapeutics shares are trading higher after the company announced a $120 million registered direct offering ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION